Clinical Effect of Cyclosporine 0.05% Eye Drops in Dry Eye Syndrome Patients.

Byun, Yong Soo; Jeon, Eun Jeong; Chung, Sung Kun

doi:2008.49.10.1583

J Korean Ophthalmol Soc > Volume 49(10); 2008 > Article

Original Article

Journal of the Korean Ophthalmological Society 2008;49(10):1583-1588.
DOI: https://doi.org/10.3341/jkos.2008.49.10.1583 Published online October 15, 2008.

Clinical Effect of Cyclosporine 0.05% Eye Drops in Dry Eye Syndrome Patients.

Yong Soo Byun, Eun Jeong Jeon, Sung Kun Chung

Department of Ophthalmology and Visual Science, St. Mary's Hospital, The College of Medicine, The Catholic University of Korea, Seoul, Korea. eyedoc@catholic.ac.kr

안구건조증 환자에서 사이클로스포린 0.05% 점안액의 임상효과

변용수ㆍ전은정ㆍ정성근

Department of Ophthalmology and Visual Science, St. Mary’s Hospital, The College of Medicine, The Catholic University of Korea, Seoul, Korea

Abstract

PURPOSE
We conducted a study to evaluate the change of tear secretion and symptoms in the patients with dry eye syndrome after using Restasis(R) (Cyclosporine 0.05% ophthalmic emulsion, Allergan Inc., U.S.A.). METHODS: We randomly selected 39 patients from newly or previously diagnosed dry eye syndrome patients and administered Restasis(R) to them. We checked their clinical parameters and symptoms over a period of 3 months. The clinical parameters evaluated were type I and type II Schirmer tests and tear break-up time, and the symptoms of dry eye syndrome were classified into pain, itching, foreign body sensation, blurred vision, and photophobia using a scoring scale for symptoms of 0 to 5. The results were analyzed with a Mann-Whitney test (P-values <0.05 was considered statistically significant). RESULTS: For 26 of 39 patients (52 eyes) on whom all tests were carried out for 3 months, there was a significant improvement after 3 months in the type I Schirmer test, type II Schirmer test, and tear break-up time (P=0.012, 0.009, 0.001, respectively). Only 14 patients completed the questionnaire for scoring of symptoms. After using Restasis(R), foreign body sensation only improved (P=0.010). CONCLUSIONS: In our study, tear secretion was increased by Restasis(R), and a greater increase in tear secretion was seen in patients with systemic disease than in patients without systemic disease. Additional patients need to be evaluated and longer-term studies need to be performed to confirm our results.

Key Words: Cyclosporine;Dry eye syndrome;Restasis(R)